Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma

Sunil D. Kumar, Jorce L. Brieva, Ignacio Danta, Adam Wanner

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Topically applied glucocorticosteroids (GS) have been shown to cause local vasoconstriction in normal skin and this phenomenon is commonly used to assess the potency of topical GS (McKenzie skin blanching test). The purpose of the present study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasoconstriction in the airway mucosa and if subjects with and without asthma have differential vascular responsiveness to GS. In 10 nonsmokers with stable asthma and 10 nonasthmatic nonsmokers, airway mucosal blood flow (Q̇aw) expressed per milliliter of anatomical dead space and the forced expiratory volume in 1 s (FEV1) were determined before and serially after inhalation of FP (88 to 1,760 μg) or placebo. Baseline mean (± SE) Q̇aw was 55.1 ± 1.0 and 44.2 ± 1.1 μl · min-1 · ml-1 in subjects with and without asthma, respectively (p < 0.001). The corresponding mean FEV1 values were 2.34 ± 0.13 and 3.22 ± 0.12 L (p < 0.001). FP at 880 μg but not placebo produced a transient decrease in mean Q̇aw with a nadir at 30 min and return toward baseline at 90 min postinhalation; the maximum mean decrease was 37% in subjects with asthma and 21% in unaffected subjects (p < 0.01); 880 μg of FP was the lowest effective dose. FEV1 did not change after FP administration in either group. These results demonstrate a transient vasoconstrictive action of inhaled FP in the airway mucosa, with a greater vascular responsiveness in subjects with asthma than in unaffected subjects. The measurement of Q̇aw may provide a more relevant means of assessing the potency of inhaled GS than the McKenzie skin blanching test. In addition, our observation suggests that inhaled GS have potentially beneficial effects in asthma that is not related to their antiinflammatory action.

Original languageEnglish
Pages (from-to)918-921
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume161
Issue number3 I
StatePublished - Apr 6 2000

Fingerprint

Asthma
Forced Expiratory Volume
Skin Tests
Vasoconstriction
Blood Vessels
Mucous Membrane
Placebos
Inhalation
Fluticasone
Anti-Inflammatory Agents
Observation
Skin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. / Kumar, Sunil D.; Brieva, Jorce L.; Danta, Ignacio; Wanner, Adam.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 161, No. 3 I, 06.04.2000, p. 918-921.

Research output: Contribution to journalArticle

@article{d81c628093fe4dc79263fac04c43a9fd,
title = "Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma",
abstract = "Topically applied glucocorticosteroids (GS) have been shown to cause local vasoconstriction in normal skin and this phenomenon is commonly used to assess the potency of topical GS (McKenzie skin blanching test). The purpose of the present study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasoconstriction in the airway mucosa and if subjects with and without asthma have differential vascular responsiveness to GS. In 10 nonsmokers with stable asthma and 10 nonasthmatic nonsmokers, airway mucosal blood flow (Q̇aw) expressed per milliliter of anatomical dead space and the forced expiratory volume in 1 s (FEV1) were determined before and serially after inhalation of FP (88 to 1,760 μg) or placebo. Baseline mean (± SE) Q̇aw was 55.1 ± 1.0 and 44.2 ± 1.1 μl · min-1 · ml-1 in subjects with and without asthma, respectively (p < 0.001). The corresponding mean FEV1 values were 2.34 ± 0.13 and 3.22 ± 0.12 L (p < 0.001). FP at 880 μg but not placebo produced a transient decrease in mean Q̇aw with a nadir at 30 min and return toward baseline at 90 min postinhalation; the maximum mean decrease was 37{\%} in subjects with asthma and 21{\%} in unaffected subjects (p < 0.01); 880 μg of FP was the lowest effective dose. FEV1 did not change after FP administration in either group. These results demonstrate a transient vasoconstrictive action of inhaled FP in the airway mucosa, with a greater vascular responsiveness in subjects with asthma than in unaffected subjects. The measurement of Q̇aw may provide a more relevant means of assessing the potency of inhaled GS than the McKenzie skin blanching test. In addition, our observation suggests that inhaled GS have potentially beneficial effects in asthma that is not related to their antiinflammatory action.",
author = "Kumar, {Sunil D.} and Brieva, {Jorce L.} and Ignacio Danta and Adam Wanner",
year = "2000",
month = "4",
day = "6",
language = "English",
volume = "161",
pages = "918--921",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma

AU - Kumar, Sunil D.

AU - Brieva, Jorce L.

AU - Danta, Ignacio

AU - Wanner, Adam

PY - 2000/4/6

Y1 - 2000/4/6

N2 - Topically applied glucocorticosteroids (GS) have been shown to cause local vasoconstriction in normal skin and this phenomenon is commonly used to assess the potency of topical GS (McKenzie skin blanching test). The purpose of the present study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasoconstriction in the airway mucosa and if subjects with and without asthma have differential vascular responsiveness to GS. In 10 nonsmokers with stable asthma and 10 nonasthmatic nonsmokers, airway mucosal blood flow (Q̇aw) expressed per milliliter of anatomical dead space and the forced expiratory volume in 1 s (FEV1) were determined before and serially after inhalation of FP (88 to 1,760 μg) or placebo. Baseline mean (± SE) Q̇aw was 55.1 ± 1.0 and 44.2 ± 1.1 μl · min-1 · ml-1 in subjects with and without asthma, respectively (p < 0.001). The corresponding mean FEV1 values were 2.34 ± 0.13 and 3.22 ± 0.12 L (p < 0.001). FP at 880 μg but not placebo produced a transient decrease in mean Q̇aw with a nadir at 30 min and return toward baseline at 90 min postinhalation; the maximum mean decrease was 37% in subjects with asthma and 21% in unaffected subjects (p < 0.01); 880 μg of FP was the lowest effective dose. FEV1 did not change after FP administration in either group. These results demonstrate a transient vasoconstrictive action of inhaled FP in the airway mucosa, with a greater vascular responsiveness in subjects with asthma than in unaffected subjects. The measurement of Q̇aw may provide a more relevant means of assessing the potency of inhaled GS than the McKenzie skin blanching test. In addition, our observation suggests that inhaled GS have potentially beneficial effects in asthma that is not related to their antiinflammatory action.

AB - Topically applied glucocorticosteroids (GS) have been shown to cause local vasoconstriction in normal skin and this phenomenon is commonly used to assess the potency of topical GS (McKenzie skin blanching test). The purpose of the present study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasoconstriction in the airway mucosa and if subjects with and without asthma have differential vascular responsiveness to GS. In 10 nonsmokers with stable asthma and 10 nonasthmatic nonsmokers, airway mucosal blood flow (Q̇aw) expressed per milliliter of anatomical dead space and the forced expiratory volume in 1 s (FEV1) were determined before and serially after inhalation of FP (88 to 1,760 μg) or placebo. Baseline mean (± SE) Q̇aw was 55.1 ± 1.0 and 44.2 ± 1.1 μl · min-1 · ml-1 in subjects with and without asthma, respectively (p < 0.001). The corresponding mean FEV1 values were 2.34 ± 0.13 and 3.22 ± 0.12 L (p < 0.001). FP at 880 μg but not placebo produced a transient decrease in mean Q̇aw with a nadir at 30 min and return toward baseline at 90 min postinhalation; the maximum mean decrease was 37% in subjects with asthma and 21% in unaffected subjects (p < 0.01); 880 μg of FP was the lowest effective dose. FEV1 did not change after FP administration in either group. These results demonstrate a transient vasoconstrictive action of inhaled FP in the airway mucosa, with a greater vascular responsiveness in subjects with asthma than in unaffected subjects. The measurement of Q̇aw may provide a more relevant means of assessing the potency of inhaled GS than the McKenzie skin blanching test. In addition, our observation suggests that inhaled GS have potentially beneficial effects in asthma that is not related to their antiinflammatory action.

UR - http://www.scopus.com/inward/record.url?scp=0034023468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034023468&partnerID=8YFLogxK

M3 - Article

VL - 161

SP - 918

EP - 921

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3 I

ER -